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Abstract – Our group is investigating the
antidepressant effects of high-dose propofol, but
dosing propofol to induce standardized changes in
EEG activity (“burst suppression”) is challenging due
to
limited
knowledge
of
each
subject’s
pharmacokinetics (PK) and pharmacodynamics (PD).
In this paper, we approximated PK-PD models for
propofol-induced burst suppression (PIBS), based on
multiple subjects over repeated treatments. We then
applied these models to predict BSR in each subject’s
repeated treatment, then evaluate their predictive
performances. We hypothesized that predicting BSR
from a greater number of previous treatments would
improve performance, but our current results are not
conclusive enough to validate the hypothesis. We
discuss
our contributions,
limitations, and
adjustments for future studies.
I.

CLINICAL BACKGROUND

An estimated 17.3 million US adults suffered a
depressive episode in 2017 [1]. One third of patients do
not respond to first-line antidepressants [2] and are left
with limited treatment options. While electroconvulsive
therapy (ECT) has been proven an effective option for
severely depressed patients [3], the induced-seizure and
patients' perceptions of ECT’s side effects may deter
many from considering it as a treatment option [4]. Novel
pharmacological alternatives are being investigated,
which include common intravenous anesthetics, for
example nitrous oxide, ketamine, isoflurane, and
propofol.
Our group is investigating the antidepressant
effects of propofol [5], an intravenous hypnotic typically
used to induce and maintain anesthesia. By suppressing
cortical activity via GABA-ergic mechanisms [6] in the
brain, propofol can directly suppress EEG activity [7]. At
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higher doses, propofol can also significantly reduce
cerebral blood flow and metabolic rate of oxygen, which
has been used to provide neuroprotection during
neurosurgery [8], and relieve intracranial hypertension [9]
and refractory status epilepticus [10].
Propofol can induce EEG patterns (“burst
suppression”) that are similar to those seen with ECT, but
without the induced seizure. Our group has reported
preliminary indications of propofol’s antidepressant
effects [11]. The burst suppression EEG pattern of
alternating periods of activity and quiescence alone may
be sufficient for antidepressant efficacy [12]. However,
accurately
controlling
propofol-induced
burst
suppression (PIBS) and administering a standardized
effect remains a challenge.

II. TECHNICAL BACKGROUND
Proper dosing of propofol to induce a
standardized level of burst suppression, across different
subjects and over repeated treatments, must consider the
variabilities in pharmacokinetics (PK, how drug
distributes throughout body) and pharmacodynamics (PD,
how drug affects body). Neither can be intraoperatively
validated nor practically estimated. Published PK-PD
models could alternatively be used to help predict BSR,
but they are not fully individualized to each subject and
still result in inaccuracies when predicting the
concentrations of propofol in the body [13].
Quantifying Burst Suppression
Burst suppression is commonly quantified by the
burst suppression ratio (BSR): the relative time that the
subject’s EEG is suppressed over a given epoch (e.g. 60
sec). Burst suppression probability (BSP) has also been
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proposed to quantify burst suppression with a statistical
basis [14].

Figure 1. EEG recording of propofol-induced burst suppression,
which includes alternating periods of “bursts” and quiescence.
Propofol suppresses the EEG, while BSR quantifies the relative time
(percentage) of suppressed EEG activity.

Pharmacokinetics
The amount of propofol administered and three
compartment PK models (e.g. Schnider, Marsh, and
Minto [15]) are typically used to estimate patients’
accumulation and decay of propofol concentration over
time. They include a central compartment along with a
fast- and a slow compartment. They account for factors
such as sex, height, age, and weight which affect the rate
constants
between
the
compartments.

BSR has not been reported before. Understanding
biophase is essential to modeling the relationships
between dose and effect-site concentration, and the
relationship between the effect-site concentration and the
observed response (PD).

Figure 3. BSR (black) and predicted effect-site concentration (pCe,
blue) during a high-dose propofol treatment. BSR generally correlates
with administration of propofol and accumulation of pCe, but the
relationship is inexact and nonlinear. The PK parameters used (Marsh
model) have not been clinically validated for BSR.

Pharmacodynamics
Pharmacodynamic models for propofol are
generally modeled through a sigmoidal Hill curve [18],
which reflect a lower threshold to observe the effect and
saturation of the effect at higher concentrations, similar to
how biochemical receptors behave [19]. Our study’s
fitted-PD models specifically relate the predicted effectsite concentration (pCe(t), mcg/mL) to the observed burst
suppression ratio (BSR) for each high-dose propofol
treatment.
Hill Equation: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =

Figure 2. Layout of a classic three compartment PK model, which
includes multiple rate constants. Drug is administered to the central
compartment; then transferred between the rapid peripheral, slow
peripheral, and effect site compartments; and eventually eliminated
from the system. Source: Al-Rifai et al. BJA Education 16(3), 2016

Given that there is generally a delay between
changes in the central compartment's concentration of
propofol and changes in observed response (e.g. BSR), a
fourth compartment is often included to represent the
“effect site” or “biophase” with its own rate constant (ke0)
[16]. Each model’s ke0 depends on the underlying PK
model and method (e.g., arterial vs. venous blood
sampling), as well as the measured effect [17]. To our
knowledge, a ke0 or PK-PD model specific to PIBS and
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pBSR represents the model’s predicted BSR. The
Hill coefficient characterizes the general steepness of the
PD response curve. The EC50 parameter defines the pCe
associated with 50% BSR.

Figure 4. pCe (same from Figure 3) plotted directly against the
observed BSR (black). Hysteresis has not yet been resolved.
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We hypothesize that predicting BSR from a
greater number of previous treatments and models will
improve the accuracy of predicting BSR.
IV. METHODS

Figure 5. Relationship between pCe vs BSR (black) improved by
optimizing the ke0 to minimize the regression’s root mean square error
(RMSE) and maximize fit to the Hill curve (red).

Model-Based Predictions
Beyond analyzing each high-dose propofol
treatment and individualizing the fit of each PK-PD
model, our group is interested in the model’s application
and utility in predicting the observed BSR over repeated
treatments, for example to guide or control propofol
dosing. However, we first need to quantify the predictive
performance of these model-based predictions before
implementation.
Example Treatment: Subject A
100
Observed BSR

90

Predicted BSR

80
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We conducted a post hoc study of an ongoing
randomized-controlled trial (NCT: NCT03684447 on
ClinicalTrials.gov) at the University of Utah. We
analyzed the high-dose propofol treatments, in which
clinicians target a BSR of 80% ± 10% for 15 min.
Propofol was the only hypnotic that was administered.
We fitted and individualized PK-PD models for propofolinduced burst suppression, then analyzed how the models
performed predicting BSR in future PIBS treatments.
Data Collection
Following IRB approval and informed consent,
each of five patients (3:2 female:male, 33-51 yo, BMI
18.3-33.9 kg/m2) underwent 4 to 8 PIBS treatments within
a 3-week period each. For each treatment, we recorded the
administered boluses and infusion rates for propofol,
along with the BSR(t) from a BIS™ Vista Monitor
(Medtronic, Dublin, Ireland).
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Figure 6. Observed BSR (blue) compared with the Predicted BSR
(magenta), which is based on an individualized PK(predicted)-PD
model from the previous treatment.

III. OBJECTIVES
Despite the challenges in predicting and
controlling BSR, we believe that dosing can be
individualized by inferring PK-PD parameters from
previous treatments. In this paper, our objectives are to 1)
approximate and optimize a PK-PD model for each highdose propofol treatment and then 2) apply models to
predict BSR in future treatments and evaluate their
performances.
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Demographic Parameters
Subject
Sex
Height (cm)
Age (yr) Weight (kg) n (1)
A
M
183
34
92
5
B
M
175
37
104
8
C
F
187
51
69
6
D
F
173
40
81
6
E
F
170
51
67
8
Table 1. Summary of the subjects’ demographic parameters, along
with the number of treatments (n) analyzed in this paper.

PK-PD Modeling
For each treatment, we derived pCe(t)
(concentration domain) from the recorded administrations
of propofol (dose domain). We used each subject’s
demographic parameters (sex, height, age, and weight) to
approximate their pharmacokinetics via Eleveld’s PK
model [17], then calculated pCe(t) (concentration) using
Shafer’s simple pocket calculator approach [20].
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patient. pBSR(t) was then derived from pCe(t) using the
Hill equation and median of the parameters (Hill
coefficient and EC50) from all of the previous treatments.
Analysis

Figure 7. A typical example of how pCe(t) changes during a high-dose
propofol treatment, which includes an initial bolus and base infusion.

We then related pCe(t) to BSR(t) for each
treatment by first optimizing ke0 to maximizing the
relationship’s fit to the Hill Equation. Specifically, we
used an iterative method to test ke0 between 0.80 and 2.00
min-1 and minimized the regression’s root mean squared
error (RMSE). After optimizing ke0, the regression for
the Hill curve provided the corresponding Hill and EC50
parameters for each treatment.
Predicting BSR from Previous Treatment(s)
For each subject, after their first treatment, we
compared each of following treatment’s BSR(t) with the
pBSR(t), which was based upon the individualized PKPD model(s) from previous treatment(s). For each
treatment after the second treatment, pBSR(t) was
determined using two methods: the “Prior Treatment”
approach (PTA) and the “Rolling Average” approach
(RAA).
Prior Treatment Approach: For each repeated
treatment, pCe(t) was derived from the original
recordings of administered propofol, by applying the
Eleveld PK model and the optimized ke0 from the
previous treatment. pBSR(t) was then derived from pCe(t)
using the Hill equation and parameters (Hill coefficient
and EC50) from the immediately preceding treatment.
Rolling Average Approach: For each repeated
treatment, pCe(t) was derived from the original
recordings of administered propofol, by applying the
Eleveld PK model and taking the median of the optimized
ke0s from all of the previous treatments of that particular
Utah NASA Space Grant Consortium

For each repeated treatment, we quantified each
approach’s performance by measuring the median
percentage error (MdPE), median absolute percentage
error (MdAPE), median magnitude error (MdME),
median absolute magnitude error (MdAME), and
Controlled—percentage of treatment time within ± 5%
BSR error [21]. Percentage error (PE) was defined as
(𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 − 𝐵𝐵𝐵𝐵𝐵𝐵𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑣𝑣𝑒𝑒𝑒𝑒 )/𝐵𝐵𝐵𝐵𝐵𝐵𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 . ME was
defined as (𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 − 𝐵𝐵𝐵𝐵𝐵𝐵𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 ).
We compiled and compared the performances
between the two BSR-prediction approaches across all
five subjects and their repeated treatments. For each
subject, the second treatments were omitted in the
comparison, because both approaches’ pBSR(t) are
derived solely from the first treatment’s individualized
model and thus equivalent.
V. RESULTS
For each subject and each of their repeated
treatments, we optimized and recorded ke0, along with
Hill and EC50. We characterized each subject’s intertreatment distribution for the three parameters in Table 2,
which offers preliminary insight into intra-subject PK/PD
variability.
PK(predicted)-PD Modeling
Param.
ke0 (min-1)
Hill
EC50 (mcg/mL)
Subject Mean CV Mean CV
Mean
CV
A
0.11
17%
6.4
46%
5.4
8%
B
0.14
53%
12.4
48%
4.3
37%
C
0.11
57%
7.2
49%
5.9
42%
D
0.11
37%
6.1
77%
6.5
23%
E
0.11
20%
8.8
45%
4.4
13%
Table 2. Summary of each subject’s optimized model parameters and
insight into their inter-treatment variabilities. Distribution
characterized by the mean and log-normal coefficients of variations
(CV).

For each subject and across their repeated
treatments, the performances for both predicted-BSR
approaches are summarized in Tables 3 and 4. Between
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different subjects, the predictive performance of each
approach also differed.
Prior Treatment Approach (PTA)
Subject MdPE MdAPE MdME MdAME Controlled
A
-2.3%
9.0%
-0.8%
4.1%
58.5%
B
-9.5%
24.4%
-2.1%
9.0%
35.8%
C
-13%
46.6%
-3.1%
18.6%
19.3%
D
0.0%
24.4%
-0.1%
14.5%
26.4%
E
1.0%
11.8%
0.4%
6.6%
39.7%
Table 3. Predictive performance for Prior Treatment Approach.
Rolling Average Approach (RAA)
Subject MdPE MdAPE MdME MdAME Controlled
A
-2.1%
9.9%
-0.7
4.7%
51.9%
B
30.7%
50.8%
4.8%
9.0%
35.6%
C
14.0%
44.4%
4.2%
13.3%
25.5%
D
1.7%
14.3%
0.5%
6.8%
35.9%
E
2.6%
10.3%
1.7%
4.3%
55.8%
Table 4. Predictive performance for Rolling Average Approach.

Table 5 shows the median performance across all
23 repeated treatments for each metric. Across treatments
and compared to the Prior Treatment Approach (PTA),
the Rolling Average Approach (RAA) improved the
Controlled metric by 11.7 percentage points. While RAA
increased the median error (MdPe, MdME), RAA
decreased the absolute error compared to PTA.
Compiled BSR-Prediction Performance
Method MdPE MdAPE MdME MdAME Controlled
PTA
-2.2%
18.1%
-0.8%
8.0%
35.8%
RAA
2.6%
14.3%
1.3%
5.5%
47.5%
Δ
+4.8%
-3.8%
+2.1%
-2.5%
+11.7%
Table 5. Compiled performances for the Prior Treatment Approach
(PTA) and Rolling Average Approach (RAA), then differences (Δ) in
performances summarized in the bottom row. Results that support
hypothesis are colored in green.

VI. DISCUSSION
In this study individualized PK-PD model
parameters were determined for PIBS, based on multiple
subjects and across repeated treatments. Our results offer
preliminary insight into inter- and intra-subject PK/PD
variabilities, which may impact the performance in
predicting BSR. Inter- and intra-subject variabilities in
model parameters, along with predictive performance,
may be confounded by demographic and clinical factors.
Compared to PTA, RAA seems to demonstrate
slightly better performance in predicting BSR, based on
the Controlled and absolute performance metrics – but
slightly worse performance based on the non-absolute
Utah NASA Space Grant Consortium

metrics. The differences do not reach statistical
significance (likely because of a too small sample size)
and do not allow conclusions about the hypothesis.
Additionally, the experiment was not designed primarily
as a pharmacokinetic or -dynamic study. RAA’s compiled
MdAPE (14.3%) to predict BSR was considerably larger
than a PD model that predicted BIS with an MdAPE of
4.85% [22].
Future studies may be warranted and should
target the PK-PD aspects in their experimental design and
pursue a larger sample size. Furthermore, different
approaches to predict BSR beyond PTA and RAA could
also be considered to test the hypothesis. This includes
how model parameters are derived from previous
treatment(s), and ways to further optimize ke0 and other
PK parameters to improve the model’s fit.
VII. CONCLUSION
Despite the challenges in dosing propofol,
understanding each subject’s unique PK/PD, and
targeting a specific BSR for a specific duration,
individualized models from previous treatments may be
helpful in predicting and controlling BSR. Standardizing
how PIBS is administered would reduce confounding in
our group’s clinical investigation, and may also be useful
in clinical practice. Our study explored model
performance across multiple treatments, but was not able
to demonstrate whether predictive performance can be
improved across repeated treatments of PIBS. Future
studies and adjustments are necessary to fully explore our
hypothesis.
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